Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US pharma giant Eli Lilly has ventured into India with an anti-obesity and diabetes drug called Mounjaro. This development ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, ...

The company’s Mounjaro and Zepbound treatments led $ ... But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is ... push underscores Lilly’s efforts to further define itself as a reliable developer and distributor of its ...

including the popular weight-loss drug Mounjaro. Eli Lilly said the investment will create 3,000 high-skilled positions and approximately 10,000 construction jobs. Eli Lilly has unveiled plans to ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...